Abstract | INTRODUCTION: Posttransplant lymphoproliferative disorder (PTLD) is a serious complication following solid organ or hematopoietic stem cell transplantation (HSCT). Although extranodal involvement of PTLD is common, its isolated involvement in the central nervous system (CNS) is extremely rare. To date, primary CNS-PTLD has been reported in 13 patients who underwent allogeneic HSCT, but no cases have been reported in autologous HSCT recipients. CASE DESCRIPTION: DISCUSSION AND EVALUATION: Given the rarity of CNS-PTLD, there is no consensus on the optimal treatment. Historically, the outcome of CNS-PTLD has been very poor. However, our patient remains free from PTLD after only total resection. The prognosis for PTLD following auto-HSCT may depend upon the underlying malignancy, immune state, EBV immune status, and treatments. CONCLUSIONS: The outcome of PTLD following auto-HSCT is not necessarily poor prognosis. Further research is required to establish the optimal treatment strategy for CNS-PTLD.
|
Authors | Hitoshi Sano, Masanobu Fujimoto, Keisuke Okuno, Jun-Ichi Ueyama, Shuichi Takano, Kazuhiko Hayashi, Susumu Kanzaki |
Journal | SpringerPlus
(Springerplus)
Vol. 3
Pg. 582
( 2014)
ISSN: 2193-1801 [Print] Switzerland |
PMID | 25332882
(Publication Type: Journal Article)
|